Extended survival with metastatic pancreatic cancer under fruquintinib treatment after failed chemotherapy: Two case reports

Figure 1 Computed tomography. A: Computed tomography revealed one reinforcing nodule anterior to the descending portion of the duodenum; B: Considered metastatic; soft tissue shadows adjacent to the celiac trunk.

Figure 2 Change in carbohydrate antigen 19-9 over time (case 1). CA19-9: Carbohydrate antigen 19-9.

Figure 3 Computed tomography scan of patient 1 after taking fruquintinib remained a stable disease for 10 months. A: Computed tomography (CT) scan of the target lesion, February 2022; B: CT scan of the target lesion, April 2022; C: CT scan of the target lesion, August 2022; D: CT scan of the target lesion, December 2022.

Figure 4 Computed tomography revealed postoperative changes in pancreatic cancer. A: Revealing cystic foci near the portal vein, multiple abdominopelvic nodules; B: Potential metastasis, and enlarged abdominal lymph nodes.

Figure 5 Change in carbohydrate antigen 19-9 over time (case 2). CA19-9: Carbohydrate antigen 19-9.

Figure 6 Computed tomography scan of case 2. The computed tomography (CT) scan revealed a continuous partial response from February 23, 2022, to December 7, 2022. A: CT scan showed the target lesion of 51 mm × 46 mm, February 2022; B: CT scan showed the target lesion of 34 mm × 38 mm, April 2022; C: CT scan showed the target lesion of 33 mm × 38 mm, June 2022; D: CT scan showed the target lesion of 35 mm × 31 mm, October 2022; E: CT scan showed the target lesion of 36 mm × 31 mm, December 2022.